vs

Side-by-side financial comparison of Oportun Financial Corp (OPRT) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Oportun Financial Corp is the larger business by last-quarter revenue ($247.7M vs $151.7M, roughly 1.6× Tarsus Pharmaceuticals, Inc.). Oportun Financial Corp runs the higher net margin — 1.4% vs -5.5%, a 6.9% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -1.3%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -0.5%).

Oportun Financial Corp is a US-based fintech firm that provides accessible, responsible financial services including personal loans, credit cards, and savings products to underserved low-to-moderate income consumers, many with limited or no credit history, leveraging proprietary AI underwriting to deliver fair terms while mitigating operational risk.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

OPRT vs TARS — Head-to-Head

Bigger by revenue
OPRT
OPRT
1.6× larger
OPRT
$247.7M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+129.7% gap
TARS
128.4%
-1.3%
OPRT
Higher net margin
OPRT
OPRT
6.9% more per $
OPRT
1.4%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-0.5%
OPRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OPRT
OPRT
TARS
TARS
Revenue
$247.7M
$151.7M
Net Profit
$3.4M
$-8.4M
Gross Margin
Operating Margin
2.6%
-5.3%
Net Margin
1.4%
-5.5%
Revenue YoY
-1.3%
128.4%
Net Profit YoY
-61.0%
63.8%
EPS (diluted)
$0.07
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OPRT
OPRT
TARS
TARS
Q4 25
$247.7M
$151.7M
Q3 25
$238.7M
$118.7M
Q2 25
$234.3M
$102.7M
Q1 25
$235.9M
$78.3M
Q4 24
$250.9M
$66.4M
Q3 24
$250.0M
$48.1M
Q2 24
$250.4M
$40.8M
Q1 24
$250.5M
$27.6M
Net Profit
OPRT
OPRT
TARS
TARS
Q4 25
$3.4M
$-8.4M
Q3 25
$5.2M
$-12.6M
Q2 25
$6.9M
$-20.3M
Q1 25
$9.8M
$-25.1M
Q4 24
$8.7M
$-23.1M
Q3 24
$-30.0M
$-23.4M
Q2 24
$-31.0M
$-33.3M
Q1 24
$-26.4M
$-35.7M
Operating Margin
OPRT
OPRT
TARS
TARS
Q4 25
2.6%
-5.3%
Q3 25
6.0%
-12.2%
Q2 25
4.3%
-21.6%
Q1 25
5.6%
-33.5%
Q4 24
89.6%
-36.8%
Q3 24
-15.8%
-52.3%
Q2 24
-19.6%
-81.6%
Q1 24
-12.2%
-136.5%
Net Margin
OPRT
OPRT
TARS
TARS
Q4 25
1.4%
-5.5%
Q3 25
2.2%
-10.6%
Q2 25
2.9%
-19.8%
Q1 25
4.1%
-32.1%
Q4 24
200.1%
-34.8%
Q3 24
-12.0%
-48.7%
Q2 24
-12.4%
-81.6%
Q1 24
-10.6%
-129.4%
EPS (diluted)
OPRT
OPRT
TARS
TARS
Q4 25
$0.07
$-0.17
Q3 25
$0.11
$-0.30
Q2 25
$0.14
$-0.48
Q1 25
$0.21
$-0.64
Q4 24
$0.26
$-0.57
Q3 24
$-0.75
$-0.61
Q2 24
$-0.78
$-0.88
Q1 24
$-0.68
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OPRT
OPRT
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$105.5M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$390.1M
$343.4M
Total Assets
$3.3B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OPRT
OPRT
TARS
TARS
Q4 25
$105.5M
$417.3M
Q3 25
$104.6M
$401.8M
Q2 25
$96.8M
$381.1M
Q1 25
$78.5M
$407.9M
Q4 24
$60.0M
$291.4M
Q3 24
$71.8M
$317.0M
Q2 24
$72.9M
$323.6M
Q1 24
$69.2M
$298.5M
Total Debt
OPRT
OPRT
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
OPRT
OPRT
TARS
TARS
Q4 25
$390.1M
$343.4M
Q3 25
$383.9M
$335.1M
Q2 25
$376.0M
$332.6M
Q1 25
$366.1M
$342.5M
Q4 24
$353.8M
$224.5M
Q3 24
$327.6M
$237.5M
Q2 24
$354.1M
$252.2M
Q1 24
$382.0M
$275.2M
Total Assets
OPRT
OPRT
TARS
TARS
Q4 25
$3.3B
$562.2M
Q3 25
$3.2B
$534.6M
Q2 25
$3.2B
$495.0M
Q1 25
$3.2B
$500.8M
Q4 24
$3.2B
$377.0M
Q3 24
$3.3B
$376.3M
Q2 24
$3.3B
$376.8M
Q1 24
$3.3B
$349.3M
Debt / Equity
OPRT
OPRT
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OPRT
OPRT
TARS
TARS
Operating Cash FlowLast quarter
$413.4M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
121.45×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OPRT
OPRT
TARS
TARS
Q4 25
$413.4M
$19.3M
Q3 25
$99.0M
$18.3M
Q2 25
$104.5M
$-29.4M
Q1 25
$101.0M
$-20.7M
Q4 24
$393.5M
$-22.2M
Q3 24
$108.5M
$-8.7M
Q2 24
$107.7M
$-14.4M
Q1 24
$85.9M
$-37.8M
Free Cash Flow
OPRT
OPRT
TARS
TARS
Q4 25
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
OPRT
OPRT
TARS
TARS
Q4 25
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
OPRT
OPRT
TARS
TARS
Q4 25
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Q1 24
0.6%
Cash Conversion
OPRT
OPRT
TARS
TARS
Q4 25
121.45×
Q3 25
19.05×
Q2 25
15.20×
Q1 25
10.34×
Q4 24
45.04×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons